Studies have confirmed that apelin peptide levels are downregulated in both plasma (Goetze et al., 2006; Chandra et al., 2011) and in the pulmonary vasculature (Alastalo et al., 2011; Kim et al., 2013) of PAH patients compared to controls. Here, APLN is linked to pulmonary arterial hypertension.